London, United Kingdom (PressExposure) December 16, 2009 -- Hoffmann-La Roche (Roche) made a $43.7 billion bid for all the outstanding shares of Genentech on 21st July, 2008. Since 1999, Roche has been a majority shareholder with 55.9 percent of Genentechâs shares. This deal amounts to $89 per share for the remaining 44% of Genentech shares.
According to the Medical eTrack estimates, the global in-vitro diagnostics market was valued at $29.1 billion in 2007 with a CAGR of 5.7 percent between 2000 and 2007. The fastest growing segments within this market are rapid tests and genetic testing. The market is expected to show high growth to a value of $42.57 billion in 2012.
The in-vitro diagnostics market is a mature market and is characterized by sustained growth due to the increase in the aging and chronically ill population. Increased awareness towards disease prevention leading to regular health screening, increasing demand for effective and accurate diagnostic techniques, and the rise in the number of diagnostic centers is driving the market for in-vitro diagnostics. The in-vitro diagnostics market is expected to grow due to emerging sectors such as genetic testing.
This analysis was taken from a research paper published by GlobalData, to download the full Research Paper for free, click below:
Access the latest In Vitro Diagnostics analysis for free at http://www.researchviews.com
ResearchViews is your number one portal for industry related news, research, analysis and deals data. ResearchViews offers up to the minute content produced by an expert team of industry analysts.
All content on the site is free to view and allows users to keep up to date with the latest developments in their chosen industry. Free daily and weekly newsletters provide a snapshot of the major issues affecting the industry. The site also features a research store, providing the user with access to premium business intelligence from some of the world's leading market research publishers.